Dosing is underway in a Phase 3 clinical trial evaluating Dermira’s (NASDAQ:DERM) lebrikizumab, an IL-13 inhibitor, in patients at least 12 years old with moderate-to-severe atopic dermatitis (AD).
The late-stage program will include another
identical Phase 3. Total enrollment in the two studies will be ~800
subjects across ~200 sites in the U.S., Europe and Asia.
Topline data from the 16-week induction period should be available in H1 2021.
Almirall S.A. (OTC:LBTSF) owns exclusive rights in Europe under a February 2019 agreement (option exercised in June).
DERM is up 3% premarket on light volume.
https://seekingalpha.com/news/3504710-dermira-3-percent-premarket-start-late-stage-development-lebrikizumab
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.